Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis

Abstract

Objective

The characteristics of oxaliplatin-induced hypersensitivity reactions (HSRs) in Chinese patients were investigated to provide a reference for patients treated with oxaliplatin.

Methods

The study reviewed the records of patients who developed oxaliplatin-induced HSRs in 17 hospitals from May 2016 to May 2017. We collected and analyzed the basic information, history of oxaliplatin administration and premedication treatments, chemotherapy cycles, HSR symptoms, and the management and outcomes of these patients.

Results

Oxaliplatin-induced HSRs were recorded in 137 patients who had been treated with oxaliplatin-containing regimens. Five different chemotherapy regimens were applied. The median infusion cycle when oxaliplatin-induced HSRs occurred was 7, and HSRs occurred during or shortly after oxaliplatin infusion. Most of the patients experienced grade 1 or grade 2 HSRs with mild symptoms of pruritis (49.64%), flushing (46.72%), chest discomfort (26.28%), and urticaria (25.55%). The majority of the patients completely recovered from HSRs following treatment with antihistamines and dexamethasone. Seven patients completed chemotherapy with oxaliplatin after the symptoms resolved with proper management.

Conclusion

The results indicate that oxaliplatin-induced HSRs remain an important issue in safely and successfully fulfilling oxaliplatin-containing chemotherapy. Further studies are needed to analyze the risk factors and establish prophylaxis for such reactions.

Keywords

oxaliplatin / hypersensitivity reaction / retrospective study / multicenter

References

[1] OhtaH, HayashiT, MuraiS, et al.. Comparison between hypersensitivity reactionstocyclesofmodifiedFOLFOX6 and XELOX therapies in patients with colorectal cancer. Cancer Chemother Pharmacol, 2017, 79(5): 1021-1029

[2] LeeSY, KangHR, SongWJ, et al.. Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure. Cancer Chemother Pharmacol, 2014, 73(2014): 1021-1029

[3] YamauchiH, GotoT, TakayoshiK, et al.. A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin. Eur J Cancer Care, 2015, 24(1): 111-116

[4] Maindrault-GoebelF, AndréT, TournigandC, et al.. Allergic-type reactions to oxaliplatin: Retrospective analysis of 42 patients. Eur J Cancer, 2005, 41(15): 2262-2267

[5] ParkSJ, LeeKY, ParkWS, et al.. Clinical Outcomes of Reintroducing Oxaliplatin to Patients with Colorectal Cancer after Mild Hypersensitivity Reactions. Oncology, 2013, 85(6): 323-327

[6] ParelM, RanchonF, NosbaumA, et al.. Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC Pharmacol Toxicol, 2014, 15: 1

[7] AroldiF, ProchiloT, BertocchiP, et al.. Oxaliplatin-induced hypersensitivity reaction: underlying mechanisms and management. J Chemother, 2015, 27(2): 63-66

[8] KolomeyevskayaNV, LeleSB, MillerA, et al.. Oxaliplatin Is a Safe Alternative Option for Patients with Recurrent Gynecologic Cancers After Hypersensitivity Reaction to Carboplatin. Int J Gynecol Cancer, 2015, 25(1): 42-48

[9] KitadaN, DanT, TakaraK, et al.. CASE REPORT Oxaliplatin-induced hypersensitivity reaction displaying marked elevation of immunoglobulin E. J Oncol Pharm Practice, 2007, 13(2007): 233-235

[10] KobayashiT, MasakiT, KogawaK, et al.. Hemoptysis and Acute Respiratory Syndrome (ARDS) as Delayed-Type Hypersensitivity After FOLFOX4 Plus Bevacizumab Treatment. Int Surg, 2013, 98(2013): 445-449

[11] BautistaMA, BautistaMA, StevensWT, et al.. Hypersensitivity reaction and acute immune mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol, 2010, 12(3): 1-8

[12] BanoN, NajamR, QaziF, et al.. Clinical Features of Oxaliplatin Induced Hypersensitivity Reactions and Therapeutic Approaches. Asian Pac J Cancer Prev, 2016, 17(4): 1637-1641

[13] SaifMW. Hypersensitivity reactions associated with oxaliplatin. Expert Opion Drug Saf, 2006, 5(5): 687-694

[14] KimBH, BradleyT, TaiJ, et al.. Hypersensitivity to Oxaliplatin: An Investigation of Incidence and Risk Factors, and Literature Review. Oncology, 2009, 76: 231-238

[15] LenzaG, HackeraUT, KernW, et al.. Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution. Anti-Cancer Drugs, 2003, 14(2013): 731-733

[16] PolyzosA, TsavarisN, GogasH, et al.. Clinical Features of Hypersensitivity Reactions to Oxaliplatin: A 10-Year Experience. Oncology, 2008, 76(1): 36-41

[17] MakriliaN, SyrigouE, KaklamanosI, et al.. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs, 2010, 2010: 207084

[18] NozawaH, MutoY, YamadaY. Desensitization to Oxaliplatin with Two Stages of Premedication in a Patient with Metastatic Rectal Cancer. Clin Therap, 2008, 30(6): 1160-1165

[19] TokiMI, SaifMW, SyrigosKN. Hypersensitivity reactions associated with oxaliplatin and their clinical management. Expert Opion Drug Saf, 2014, 13(11): 1545-1554

[20] GammonD, BhargavaP, MccormickMJ. Hypersensitivity Reactions to Oxaliplatin and the Application of a Desensitization Protocol. Oncologist, 2004, 9: 546-549

[21] SyrigouEI, KarapanagiotouEM, AlamaraCV, et al.. Hypersensitivity Reactions to Oxaliplatin: A Retrospective Study and the Development of a Desensitization Protocol. Clin Colorectal Cancer, 2009, 8(2): 106-109

[22] SiuSWK, ChanRTT, AuGKH. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol, 2006, 17: 259-261

[23] WaddleM, IrvinM, GuptaE, et al.. Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion. Chemotherapy, 2017, 62(5): 295-300

[24] LaiJ, WangW. Acute hemolysis after receiving oxaliplatin treatment: a case report and literature review. Pharm World Sci, 2009, 31(5): 538-541

[25] GarciazS, Oziel-TaiebS, DermecheS, et al.. Acute immune hematological complication of oxaliplatin. A series of 3 cases. Tumori, 2014, 100(1): e17-e19

[26] PhullP, QuillenK, HartshornKL. Acute Oxaliplatin-induced Hemolytic Anemia, Thrombocytopenia, and Renal Failure: Case Report and a Literature Review. Clin Colorectal Cancer, 2017, 16(2): e105-e107

[27] González-MahaveI, Lobera IabairuT, Blasco SarramiánA, et al.. Anaphylaxis produced by oxaliplatin. J Investig Allergol Clin immunol, 2005, 15(1): 75

[28] ShaoY, HongR. Fatal Thrombocytopenia after Oxaliplatin-based Chemotherapy. Anticancer Res, 2008, 28(2008): 3115-3118

[29] KideraY, SatohT, UedaS, et al.. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol, 2011, 16(2011): 244-249

[30] PaganiM, BonadonnaP. Skin Test Protocol for the Prevention of Hypersensitivity Reactions to Oxaliplatin. Anticancer Res, 2014, 34(2014): 537-540

[31] GarufiC, CristaudoA, VanniB, et al.. Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol, 2003, 14: 497-498

[32] ZhangX, ZhaoY, ZhengY, et al.. The Effects of Prolonged Infusion on Reducing Oxaliplatin Hypersensitivity Reactions. J Investig Allergol Clin Immunol, 2017, 27(1): 65-66

[33] YanaiT, IwasaS, HashimotoH, et al.. Successful Rechallenge for Oxaliplatin Hypersensitivity Reactions in Patients with Metastatic Colorectal Cancer. Anticancer Res, 2012, 32: 5521-5526

[34] RosePG, MetzC, LinkN. Desensitization With Oxaliplatin in Patients Intolerant of Carboplatin Desensitization. Int J Gynecoll Cancer, 2014, 24(9): 1603-1606

[35] EdmondsonDA, GrulingBJ, UrmanskiAM, et al.. Oxaliplatin Hypersensitivity: Case Report and Successful Repeat Desensitization. Am J Therapeut, 2007, 14(2007): 116-118

[36] WongJT, LingM, PatilS, et al.. Oxaliplatin Hypersensitivity: Evaluation, Implications of Skin Testing, and Desensitization. J Allergy Clin Immunol Pract, 2013, 2(1): 40-45